adagrasib
Mirati Therapeutics' Krazati Approved in Europe for KRAS G12C-Mutant NSCLC
The approval was based on data from 116 NSCLC patients in the Phase II KRYSTAL-1 study.
UK's MHRA Conditionally Approves Mirati's Krazati for Advanced KRAS-Mutated NSCLC
The agency granted Mirati a license for the drug in previously treated, advanced KRAS G12C-mutated NSCLC based on data from the KRYSTAL-1 trial.
Kura Oncology, Mirati Partner to Study KO-2806 With Krazati in KRAS-Mutant NSCLC
Kura will evaluate its farnesyl transferase inhibitor with Krazati in an ongoing Phase I study of the drug.
Executives noted that its two recent acquisitions, Mirati Therapeutics and Turning Point Therapeutics, underscore its shift away from immunotherapy.
Krazati-Keytruda Combo Boasts 63 Percent Response Rate in Frontline Lung Cancer Study at ESMO
In an updated analysis from KRYSTAL-7, researchers highlighted the tolerability and low rates of severe liver toxicity among patients on the regimen.